Cynata Therapeutics Limited
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CYP.AX | CELZ | BRTX | GDTC | CELU | BCDA | |
|---|---|---|---|---|---|---|
| Market cap | 4.38M | 4.95M | 2.09M | 10.61M | 26.25M | 13.82M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.2 | -0.7 | -0.1 | -5.9 | -1.4 | -1.6 |
| Price/book | -6.5 | 0.5 | 0.6 | 2.7 | -0.7 | 5.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −94.47% | −75.95% | −94.93% | −56.87% | −55.60% | −28.91% |
| Today | 0.00% | −3.21% | +2.03% | −2.31% | −1.02% | −0.92% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All CYP.AX news ›Cynata Therapeutics Announces Issuance of 30.4 Million Unquoted Deferred Options Expiring May 2029
Kalkine Media Cynata Therapeutics Limited (ASX:CYP) CYP (ASX:CYP) has issued 30,431,834 unquoted options expiring on 3 May 2029 (ASX code: CYPAY). These options were issued on 3 November 2026 as free a
Cynata Therapeutics Limited (ASX:CYP): Clinical Trial Results Shape Regenerative Medicine Priorities
Kalkine Highlights Cynata is developing mesenchymal stem cell therapies manufactured using its Cymerus platform The company disclosed primary evaluation results for its graft-versus-host disease pro
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- kalkinemedia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.